Cempra
Inc. (Nasdaq: CEMP) reported positive data from a Phase 3 clinical trial of
intravenous to oral solithromycin to treat patients with
community-acquired bacterial pneumonia but the stock price plunged $7.88 to $18.90.
Cempra reports positive trial data but stoc
October 16, 2015 at 12:49 PM EDT